PNC Financial Services Group
KYTX icon

PNC Financial Services Group’s Kyverna Therapeutics KYTX Stock Holding History

PNC Financial Services Group’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.6K Hold
1,530
– – ﹤0.01% 3953
2026
Q1 		$13.2K Sell
1,530
-138
-8% -$1.15K ﹤0.01% 3855
2025
Q4 		$15.7K Hold
1,668
– – ﹤0.01% 3774
2025
Q3 		$10K Sell
1,668
-282
-14% -$1.13K ﹤0.01% 3940
2025
Q2 		$5.99K Buy
1,950
+480
+33% +$1.19K ﹤0.01% 4056
2025
Q1 		$2.84K Buy
+1,470
New +$4.34K ﹤0.01% 4250

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

PNC Financial Services Group's KYTX Position: Q2 2026 in Review

PNC Financial Services Group held its Kyverna Therapeutics (KYTX) position steady in Q2 2026 at 1,530 shares worth $13.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3953.

PNC Financial Services Group first reported a position in KYTX in Q1 2025 and has held it in 6 quarters since. The position peaked at $15.7K in Q4 2025. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • PNC Financial Services Group held 1,530 shares of Kyverna Therapeutics worth $13.6K as of Q2 2026.
  • PNC Financial Services Group left its Kyverna Therapeutics share count unchanged in Q2 2026.
  • Kyverna Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #3953 holding.
  • PNC Financial Services Group first reported a position in Kyverna Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • PNC Financial Services Group's Kyverna Therapeutics position peaked at $15.7K in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.